tbuckley/cabot-search huggingface dataset:
1391TiP TACTC-2 trial: Efficacy of pembrolizumab ± chemotherapy first-line therapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50% adjusting in accordance with CtDNA
Authors: Z.W. Xu, Y. Xiang, X.W. Sun, L. Mengchen, X.X. Feng, Z. Ran, Y. Jin, L. Zhou, B. Gao, J. Zhou, Q. Zhang, Q. Chen
Journal: Annals of Oncology (2024)
1358P Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Authors: T.M. Feinstein, B. Han, Y-K. Shi, G. Chen, Y. Yao, C. Hu, J. Shi, J. Feng, H. Wu, Y. Cheng, Q. Guo, Z. Jie, F. Ye, Y. Zhang, Z. Liu, W.D. Mao, L. Bazhenova, Y. Wu, L. Huang, Y. Sun
Journal: Annals of Oncology (2024)
1395TiP A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)
Authors: A. Passaro, J.C. Brase, J. Xu, L. Mongay Soler, K. Goto
Journal: Annals of Oncology (2024)
1414P Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II study
Authors: W. Zhang, T. Zhang, X. Chen, J. Li, Z. Zheng, J. Dong, Z. Li, G. Zhao, F. Cao, P. Wang, C. Yan, Q. Pang
Journal: Annals of Oncology (2024)
1379P c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study
Authors: J. Bar, S. Baijal, A. Luo, N. Zhang, C. Ratajczak, P.J. Ansell, S. Lu, D.R. Camidge
Journal: Annals of Oncology (2024)
1355P Real-world (RW) treatment patterns and survival outcomes by PD-L1 expression in stage IV non-squamous (nsq) non-small cell lung cancer (NSCLC): A retrospective analysis of the UK National Cancer Registry Database (NCRAS)
Authors: F. Gomes, H. Lee, F. Ingleby, I. Bouajila, P. Sudhapalli, E. Chaparova, Y. Zheng
Journal: Annals of Oncology (2024)
1373P Measuring PFS in clinical trials and observational studies of patients with NSCLC: A scoping review
Authors: M. Verschueren, V. Tassopoulou, R. Visscher, J. Schuurkamp, B. Peters, M. Koopman, E. van de Garde, T. Egberts, L.T. Bloem
Journal: Annals of Oncology (2024)
1356P Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Authors: E. Marin, C. Aguado, A. Giménez-Capitán, P. Gausà-Busquets, R.M. Reyes Cabanillas, A. Arcocha, M. Querol, C. Teixido, M.A. Molina-Vila, N. Reguart Aransay
Journal: Annals of Oncology (2024)
1417P Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons
Authors: E.C. Smyth, J.A. Ajani, K. Wang, J. Coaquira Castro, M. Figueiredo, J-M. Sun, K. Soulanis, A. Tasoulas, G. Nikolaidis, E. Priedane, L. Zhan
Journal: Annals of Oncology (2024)
1416P First-line tislelizumab combined with bevacizumab and CAPOX for metastatic gastroesophageal adenocarcinoma (mGEA) with PD-L1 CPS&lt;5: Updated results of a phase II, prospective, single-arm study
Authors: G. Dai, Y. Wang, R. Jia, Z. Wang, H. Si, L. Han, M. Gou, Z. Tan, L. Han, D-Z. Jiang
Journal: Annals of Oncology (2024)
1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma
Authors: Y.Y. Janjigian, A. Kawazoe, Y. Bai, J. Xu, S. Lonardi, J-P. Metges, P.E. Yanez Weber, L.S. Wyrwicz, L. Shen, Y.V. Ostapenko, M. Bilici, H.C. Chung, K. Shitara, M. Mahave, E. Van Cutsem, J. Tabernero, L. Xu, K. Sharan, P. Bhagia, S.Y. Rha
Journal: Annals of Oncology (2024)
1384P Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)
Authors: Y. Sato, Y. Tani, H. Ishii, S. Katakura, M. Oki, Y. Watanabe, T. Yokoyama, K. Naoki, J-F. Pouliot, A.J. Paccaly, E. Kim, J. Mani, S. Li, I. Lowy, F. Seebach, M.D. Mathias, S. Ikeda
Journal: Annals of Oncology (2024)
1364P Federated analysis of overall survival (OS) by location of metastases (mets) in patients (pts) with metastatic NSCLC (mNSCLC) from the Digital Oncology Network for Europe (DigiONE)
Authors: Å.K. Öjlert, P. Jain, L.E. Hendriks, F.R. Ogliari, F. Acker, E. Bolton, O. Bouissou, J. Brash, A-L. Bynens, S. Cheeseman, H.M. Fenton, P. Galgane Banduge, T. Goering, A. Lobo Gomes, R. McDonald, E. Ross, L. Sanchez Gomez, S. Theophanous, I. Zhovannik, A. Helland
Journal: Annals of Oncology (2024)
1411P AI-powered immune phenotype predicts favorable outcomes of nivolumab (niv) plus chemotherapy (chemo) in advanced fgastric cancer (AGC): A multi-center real-world data analysis
Authors: H-D. Kim, C-K. Lee, S.I. Cho, S. Hwang, S. Song, H.Y. Kay, C-Y. Ock, Y.S. Park, M. Jung, M.H. Ryu
Journal: Annals of Oncology (2024)
1413P Multi-modal deep-learning model for real-time prediction of recurrence in early-stage esophageal cancer: A multi-modal approach
Authors: H.A. Jung, D. Lee, B. Park, K. Lee, H.Y. Lee, T.J. Kim, Y.J. Jeon, J. Lee, J.H. Cho, H.K. Kim, Y.S. Choi, S. Park, J-M. Sun, S-H. Lee, J.S. Ahn, M-J. Ahn
Journal: Annals of Oncology (2024)
1353P Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Authors: K. Ferentinos, A. Traut, P.B. Czyborra, W. Langer, H. Nueckel, C-V. Hannig, J. Volmerig, G. Nilius, D.C. Christoph
Journal: Annals of Oncology (2024)
1352P Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Authors: M. Russano, L. Cantini, A.P. B, R. George, P. Nunes, K. Tolba, C. Dutra, I. Chico, A. Cortellini, F. Pecci, J.V. Alessi, B. Ricciuti, S. Ramkissoon, J.G. Aerts, S. Agrawal, K.S. Saini
Journal: Annals of Oncology (2024)
1369P Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: A prospective, single-arm, phase II clinical trial
Authors: S.C. Fang, L.F. Yang, T. Xu, X.Y. Wang, W.W. Cheng, S. Xu, N. Liu
Journal: Annals of Oncology (2024)
1419P Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G/GEJ cancer (TranStar102)
Authors: L. Shen, Z. Guo, J. Zhang, W. Guo, M. Sun, N. Xu, C. Qi, X. Zhu, L. Zhang, L. Xu, C. Germa
Journal: Annals of Oncology (2024)
1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
Authors: Y.Y. Janjigian, H.W.M. van Laarhoven, S.Y. Rha, V. Kozlov, D-Y. Oh, A. Gravina, L. Rapatoni, H. Shoji, R.D. Hofheinz, L-T. Chen, H.E.R. Ford, M. Chenard-Poirier, S. Raoufmoghaddam, C. Lloyd, C. Zhang, C. Mateo, J. Lee
Journal: Annals of Oncology (2024)
1415P Real-world data on the use of nivolumab plus chemotherapy for patients with metastatic GC/GEJC/EAC: A Canadian perspective
Authors: M. Tehfe, S. Snow, H. Lim, E. Elimova, F. Brellier, N. Dourdin, C. Brezden-Masley
Journal: Annals of Oncology (2024)
1404P Predictive role of circulating cytokines in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD1 inhibitor: Pooled analyses of two phase II clinical trials
Authors: B. Chen, S. Wang, R. Wang, X. Cheng, B. Chen, M. Dragomir, S. Liu, Y. Zhu, H. Yang, Q. Li, M. Xi
Journal: Annals of Oncology (2024)
1398TiP Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Authors: S. Peters, C.M. De Cerqueira Mathias, M.L. Cheng, B. Bridges, D. Planchard, M. Reck, R.A. Soo, Y. Zhu, E. Kim, N. Yamamoto
Journal: Annals of Oncology (2024)
1375P Sequential ctDNA profiling in patients with advanced non-small cell lung cancer: An interim analysis of the COPE randomized study
Authors: A. Italiano, L. Phan, S. Le Moulec, T. Grellety, C. Lecaille, V. Cochin, S. Schneider, M. Sabatini, L. Leroy, A. Tasseel, M. Cabart, F. Chomy, Y. Laizet, I. Soubeyran, A. Crombe, S. Cousin
Journal: Annals of Oncology (2024)
1367P Sex disparities in patient and tumour characteristics, and overall survival in advanced non-small cell lung cancer (NSCLC) within the precision oncology era: A Danish nationwide observational study
Authors: M.G. Frost, K. Jensen, E. Jimenez-Solem, C. Qvortrup, J.A. Andersen, T.S. Petersen
Journal: Annals of Oncology (2024)
1390P Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour
Authors: I. Duparc, E. Castanet, C. Basse, V. Fallet, S. Baldacci, P. Demontrond, Y. Oulkhouir, S. Cousin, D. Arpin, P. Fournel, D. Leite Ferreira, N. Piton, F. Guisier
Journal: Annals of Oncology (2024)
1359P Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy
Authors: A. Meisel, R. von Moos, A. Haider, L. Holer, S. Hayoz, S. Bengs, V. Treyer, R. Abedian, S. Websky, S.I. Rothschild, M.J. Hochmair, D.R. Gandara, F. Cappuzzo, M. Reck, F. Stenner-Liewen, M.T. Mark
Journal: Annals of Oncology (2024)
1388P Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315)
Authors: F. Griesinger, W.E.E. Eberhardt, M. Jaenicke, A. Fleitz, P. Ludwig, A. Groth, W. Weichert, M. Sebastian, M. Thomas
Journal: Annals of Oncology (2024)
1396TiP Osimertinib combined with dalpiciclib in EGFR-mutant, CDK4/6 pathway-altered, advanced NSCLC patients with acquired resistance to third-generation EGFR-TKIs: A phase II, prospective, multicenter, single-arm clinical trial
Authors: X. Jiang, M. Li, R. Jiang, C. Huang, D. Huang, P. Chen
Journal: Annals of Oncology (2024)
1376P Early detection of disease progression in NSCLC patients undergoing immunotherapy through ctDNA analysis
Authors: V. Calvo de Juan, L. Robado de Lope, A. Collazo Lorduy, M. Blanco Clemente, S. Peña Cabia, S. Sequero Lopez, B. Massuti Sureda, P. Diz Tain, S. Vazquez Estevez, X. Mielgo Rubio, J.M. Oramas Rodriguez, M.A. Sala Gonzalez, A. Lopez Martin, J. Rogado, A. Sanchez Hernandez, J. Coves Sarto, J.L. Gonzalez-Larriba, A.M. Martinez De Castro, A. Romero, M. Provencio Pulla
Journal: Annals of Oncology (2024)
1410P Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): Subgroup analysis from FRUTIGA study
Authors: L. Shen, R-H. Xu, F. Wang, W. Guo, T. Liu, J. Li, S. Qin, Y. Bai, Z. Chen, J. Wang, Y. Pan, Y. Shu, F. Zhao, Y. Cheng, F. Ye, K. Gu, T. Zhang, H. Pan, B. Zhang, M. Shi
Journal: Annals of Oncology (2024)
1392TiP Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
Authors: P.W. Cobb, M. Hochmair, M.H.H. Schuler, G.J. Riely, C.I. Rojas, S.J. Kim, X. Chen, H. Lara-Guerra, E. Felip
Journal: Annals of Oncology (2024)
1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
Authors: M.C. Garassino, P.A. Jänne, F. Barlesi, A.I. Spira, T.S.K. Mok, M. Hochmair, K.J. O'Byrne, E. Felip, S-W. Kim, F. Cappuzzo, J. Naidoo, M. Safadi, B. Wamil, J. He, M. Reck
Journal: Annals of Oncology (2024)
1408P DVDMS (Sinoporphyrin sodium)-mediated photodynamic therapy (PDT) vs treatment of physician’s choice in patients with advanced esophageal cancer (EC): Preliminary results of DYNA-Esophagus03, a randomized, open-labeled, multicenter phase IIIb study
Authors: J. Zhou, S.G. Gao, L. Xing, J. Liu, J. Wang, Y. Shu, B. Tuo, L. Cui, L. Wan, W. Bai, J. Zhao, F. Ning, Y. Ji, B. Xia, X. Jiang, L. Li, G. Xu, Z. Lu, S. Zhang, L. Shen
Journal: Annals of Oncology (2024)
1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
Authors: M. Pérol, M. Awad, S. Devarakonda, J-J. Yang, Y. Zhang, L. Wu, J. Hu, Z. Wang, D. Planchard, P. Garrido Lopez, C. Lindsay, M. Moore, A. Bulotta, E. Carcereny, M. Provencio Pulla, J.C-H. Yang, D.R. Spigel, E. Nadal, K-H.P. Yu, Y-L. Wu
Journal: Annals of Oncology (2024)
1371P An anti-EpCAM x CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion in NSCLC patients: Intermediate results of a prospective multicenter phase Ib trial
Authors: J. Cai, F. Zhang, Z. Song, J. Jin, D. Lv, W. Pang, T. Yi, G. Wang, J. Yao, B. Wang, P. Zhou, S. Huang, M. Pei, L. Huang
Journal: Annals of Oncology (2024)
1361P The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Authors: A.V. Koulouris, M.C. Skribek, C. Kamali, O. Grundberg, E. Lampa, M. Gubanski, P. Hydbring, S. Ekman, G. Tsakonas
Journal: Annals of Oncology (2024)
1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
Authors: J. Ciccolini, M. Hamimed, S. Marolleau, C. Perez, S. Benzekry, M. Le Ray, A. Boyer, C. Audigier-Valette, S. Martinez, H. Pegliasco, P. Ray, L. Falchero, A. Serre, N. Cloarec, L. Lebas, S. Hominal, J. Mazieres, M. Pérol, L. Greillier, F. Barlesi
Journal: Annals of Oncology (2024)
1374P Analysis of evolution of patient reported side effects during treatment for advanced NSCLC
Authors: H. Linardou, T. Kosmidis, K. Papadopoulou, N. Korfiatis, A. Vozikis, S. Lampaki, A. Psyrri, E. Fountzilas, A.N. Christopoulou, E. Samantas, A. Vagionas, G. Mountzios, G. Goumas, N.G. Tsoukalas, I. Athanasiadis, D. Bafaloukos, C.G. Panopoulos, M.I. Koufaki, G. Fountzilas, P.A. Kosmidis
Journal: Annals of Oncology (2024)
1397TiP Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
Authors: S.V. Liu, R. Dziadziuszko, S. Viteri, F. Cappuzzo, S. Comis, V. Gabarre, C. Chevalier, T. Vandewalle, F. Montestruc, B. Vasseur, J. Remon Masip, B. Besse
Journal: Annals of Oncology (2024)
1363P An AI-derived tool to pre-screen lung cancer candidates for clinical trials
Authors: M. Aldea, P. Rolland, L. Zullo, A. Poplu, S. Simon, A. Djarallah, M. Wartelle, L. Chutto, B. Vignal, F. Lion, S. Platano, A. Gazzah, C. Robert, F. André, F. Barlesi, S. Michiels, C. Baldini, C.P. Massard, F. Le Ouay, B. Besse
Journal: Annals of Oncology (2024)
1344P Plasma proteomics indicated predictive biomarkers for immuno-chemotherapy in stage IIIB-IV non-small cell lung cancer without EGFR/ALK alterations
Authors: Z. Hu, J. Wang, C. Zhu, X. Zhang, S. Huang, S. Sun, Z. Wu, Y. Zhang, Y. Lin, J. Wang, T. Hu, X. Li, H. Yu, X. Zhao, H. Wang, X. Wu
Journal: Annals of Oncology (2024)
1346P A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
Authors: J.C. Murray, Q. Huang, C. Hu, E. Curran, C. Wong, L. Glatz, T. Wang, A. Hasan, L. Villaruz, A. Schoenfeld
Journal: Annals of Oncology (2024)
1266P Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohort
Authors: A. Tufman, F. Manapov, S. Worthmann, W.M. Brueckl, E.L. Buchmeier, J. Stratmann, N. Frost, C. Schulz, J.K. Kern, H. Löffler, T.C. Wehler, L. Käsmann, C. Eze, R.M. Huber, D. Kauffmann-Guerrero
Journal: Annals of Oncology (2024)
1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
Authors: B. Besse, A.E. Drilon, B.C. Cho, D.R. Camidge, J. Neal, C-C. Lin, S.V. Liu, M. Nagasaka, S.C-H. Kao, E. Felip, A.J. Van Der Wekken, C.C. Lin, J.R. Bauman, S. Gadgeel, M. Samant, J. Shen, Y. Sun, V.W. Zhu, V.A. Upadhyay, J.J. Lin
Journal: Annals of Oncology (2024)
1189P Cancer genome interpreter: A data-driven tool for tumor mutation interpretation
Authors: S. Demajo, O. Tort, M. Sánchez-Guixé, F. Muiños, P. Gomis Rosa, C. López-Elorduy, M. Guardiola Fernandez, F. Brando, M. Grau, J. Deu-Pons, A. Gonzalez-Perez, N. López-Bigas
Journal: Annals of Oncology (2024)
1183P Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk
Authors: C.A. Dilaveri, C.H. McDonnell, E.A. Klein, R. Reid, C.R. Marinac, L. Nadauld, K.C. Chung, M. Lopatin, E.T. Fung, D. Schrag, D.L. Patrick
Journal: Annals of Oncology (2024)
1202P A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Authors: C. Parmar, A. Juan Ramon, P. Raciti, K. Standish, S. Chowdhury, S. Shah, F. Cruz-Guilloty, J.C. Curtin, M. Baig, R.W. Schnepp, X. Lyu, Z. Albertyn, C. Moy, J. Greshock, L. Demirdjian
Journal: Annals of Oncology (2024)
1230P Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study
Authors: M. Provencio Pulla, L. Berry, M. Quintana, T.W. LeBlanc, C. Mascaux, M. Schabath, C.M. Bestvina, M. Tratt, A.S. Mansfield, M. Bates, R.D. Gentzler, N. Girard, S. Couraud, C.J. Tan, M. Wislez, B. Wei, C. Calvet, D.A. Berry, L. Vo, D. Stenehjem
Journal: Annals of Oncology (2024)
1263P Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)
Authors: H. Yoshioka, A. Nakamura, K. Sakai, K. Nishio, K. Yonesaka, T. Misumi, T. Yokoyama, H. Itani, M. Tachihara, H. Kanemura, H. Akamatsu, A. Ono, H. Ishikawa, N. Yamamoto, H. Okamoto, T. Kurata
Journal: Annals of Oncology (2024)
1124P Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study
Authors: E. Livingstone, A. Forschner, J.C. Hassel, I. von Wasielewski, F. Meier, P. Mohr, K.C. Kähler, B. Schilling, M. Erdmann, C. Berking, S. Huning, H. Stege, R. Gutzmer, B. Kowall, A. Stang, W. Galetzka, A. Hauschild, L. Zimmer, D. Schadendorf, G.C. Lodde
Journal: Annals of Oncology (2024)
1247P Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)
Authors: A.R. Filippi, J. Bar, D.C. Christoph, J.K. Field, R. Fietkau, M.C. Garassino, P. Garrido Lopez, V.D. Haakensen, S.C-H. Kao, F. McDonald, F. Mornex, M. Moskovitz, S. Peters, M. van den Heuvel, P. Vercauter, H.J.M. Smit, P. Chander, Y. Qiao, J. Faria, N. Girard
Journal: Annals of Oncology (2024)
1269P Preventing infusion-related reactions with intravenous amivantamab: Updated results from SKIPPirr, a phase II study
Authors: L.G. Paz-Ares, A.I. Spira, J-Y. Han, J-Y. Shih, C. Mascaux, U. Basu Roy, J. Zugazagoitia, Y.J. Kim, C.H. Chiu, S-W. Kim, E. Nadal, I. Gil Bazo, P. Mahadevia, B. Anderson, K. Xia, G. Wang, J.M. Bauml, M. Chioda, J. Simões, G. Lopes
Journal: Annals of Oncology (2024)
1233P Genomic scarring score as a criterion for PARP inhibitor administration in early-stage NSCLC
Authors: A. Klinakis, K. Tsilingiri, A. Chalari, A. Voutsina, G. Christopoulou, G. Vatselas, K. Potaris, I. Vamvakaris, D. Hatzidaki, G. Zachou, V. Georgoulias, P. Konstantoulakis, A. Kotsakis
Journal: Annals of Oncology (2024)
1260P Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study
Authors: L. Doucet, L. Greillier, D. Planchard, J. Mazieres, E. Felip, J. Bosch-Barrera, M. Cobo Dols, F. Ghiringhelli, A. Bearz, L.G. Paz-Ares, M. Tiseo, E. Carcereny, G. Zalcman, V.P. Di Noia, J. de Castro Carpeño, H.J. Soto Parra, J. Corral Jaime, L. Zheng, J.C-H. Yang, P.A. Jänne
Journal: Annals of Oncology (2024)
1270P Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial
Authors: S. Park, H.K. Ahn, S. Lee, Y.J. Min, H.A. Jung, J-M. Sun, S-H. Lee, J.S. Ahn, M-J. Ahn, J.B. Lee, S.M. Lim, H.R. Kim, B.C. Cho, M.H. Hong
Journal: Annals of Oncology (2024)
1251P Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial
Authors: E. Olmetto, C. Mattioli, S. Caini, M. Del Riccio, P. Garlatti, G. Finocchiaro, P. Borghetti, G. Metro, S. Pilotto, F. Grossi, G. Farina, F.A. Meriggi, A. Sbrana, E. Roca, A. Delmonte, A. Russo, M. Macerelli, M. Perna, A. Bruni, V. Scotti
Journal: Annals of Oncology (2024)
1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
Authors: B.J. Solomon, Y-L. Wu, R. Dziadziuszko, F. Barlesi, M. Nishio, J.S. Ahn, H. Horinouchi, M.J. Hochmair, F. de Marinis, M.R. Migliorino, A. Kurochkin, H. Harputluoglu, D. Planchard, K. Korphaisarn, J-Y. Han, T. Lohmann, A. Cardona Gavaldon, V.R. Archer, M. Nowicka, J. Noe
Journal: Annals of Oncology (2024)
1178P EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis
Authors: C.M. Vanderbilt, S. Nanda, S. Singi, R. Gupta, G. Goldgof, O. Ardon, A. Elkrief, T. Fuchs, G. Campanella, M. Hameed, A. Dogan, N. Kumar
Journal: Annals of Oncology (2024)
1234P Stage migration in resectable NSCLC
Authors: G.V.D. Heuvel, B. Mandos, O. Schuurbiers, E. Aarntzen, F. Ciompi, K. Azijli, I. Walraven, H.J.M. Smit, M. van den Heuvel
Journal: Annals of Oncology (2024)
1167P Outcomes of local and systemic treatment in primary hepatic neuroendocrine neoplasms (PHNEN)
Authors: L. Apostolidis, L. de Mestier du Bourg, Z. Kender, V. Flegka, E.C. Winkler, S. Krug, C. Kratochwil, O. Hentic Dhome, P. Ruszniewski, J. Cros, B. Goeppert, S. Roessler
Journal: Annals of Oncology (2024)
1080MO Sitravatinib plus tislelizumab for metastatic uveal melanoma with liver metastasis: The open-label, multicenter, phase II GEM-2101 trial
Authors: L.P. de Carpio Huerta, E. Espinosa, L. de la Cruz Merino, A. Berrocal-Jaime, J.M. Piulats
Journal: Annals of Oncology (2024)
1108P Impact of quantitative imaging of all disease on the prognostic value of 18F-FDG PET/CT in patients treated with immunotherapy for metastatic melanoma
Authors: R. Jeraj, O. Lokre, M. Dell'Oro, R. Francis, E. Gray, T. Perk, M. Ebert, M. Millward
Journal: Annals of Oncology (2024)
1113P A machine learning model based on computed tomography radiomics to predict prognosis in subjects with stage IV melanoma
Authors: M.T. Maccallini, M. Russillo, L. Miseo, M. Cerro, A. Valenti, I. Falcone, S. Ungania, E. Gallo, F. Valenti, V. Ferraresi, A. Guerrisi
Journal: Annals of Oncology (2024)
1129P Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM)
Authors: P. Nathan, J.N. Tharakan, J.J. Sacco, J. Proudfoot-Jones, A. Furness, D.J. McMahon, L. Pallan, L.T. Khoja, P. Serra-Bellver, D. Ranatunge, O. Oladipo, G. Clements, L. Mariappan, T. Talbot, J. Nobes, T.J. Carter, H. Shaw
Journal: Annals of Oncology (2024)
1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
Authors: J. Chan, S. Geyer, T. Zemla, M.V. Knopp, S.C. Behr, S. Pulsipher, J. Acoba, A. Shergill, E.M. Wolin, T.R. Halfdanarson, B. Konda, N. Trikalinos, S. Shaheen, N. Vijayvergia, N.A. Dasari, J. Strosberg, E.C. Kohn, M. Kulke, E.M. O'Reilly, J. Meyerhardt
Journal: Annals of Oncology (2024)
1162P Transcriptomic analysis of gastroenteropancreatic neuroendocrine tumours with carcinoid syndrome
Authors: J. Pozas Perez, T. Alonso Gordoa, I. Ruz-Caracuel, T. Caniego-Casas, C. Gonzalez Merino, M.V. San Roman Gil, V. Albarrán Fernández, A.R. Granados, J.M. Rodellar, M. Viana Aragonés, J. Palacios Calvo, P. Garrido Lopez, J. Molina Cerrillo
Journal: Annals of Oncology (2024)